Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


TeenVaxView


Facebook
        Twitter
        LinkedIn
        Syndicate





Supplementary tables for Estimated Vaccination Coverage with Selected Vaccines and Doses Among Adolescents Aged 13–17 Years and Total Survey Error — National Immunization Survey–Teen, United States, 2020										Related Pages
					Online Supplementary Table 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13-17 years*, by race/ethnicity†– National Immunization Survey-Teen, United States, 2020
Online Supplementary Table 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13-17 years*, by race/ethnicity†- National Immunization Survey-Teen (NIS-Teen), United States, 2020
Vaccines
Race/Ethnicity, % (95% CI)§White only, non-Hispanic
(n = 12,582)
Black only,
non-Hispanic
(n = 1,671)
Hispanic
(n = 3,410)
American Indian/Alaska Native only, non-Hispanic
(n = 252)
Asian, non-Hispanic
(n = 808)
Multiracial,
non-Hispanic
(n = 1,367)Tdap¶ ≥ 1 dose
91.5 (90.6 to 92.4)
89.0 (86.3 to 91.2)
87.6 (84.9 to 89.9) **
88.7 (76.9 to 94.9)
90.8 (87.0 to 93.6)
90.6 (87.5 to 93.0)MenACWY††≥1 dose
89.3 (88.2 to 90.3)
89.4 (87.0 to 91.4)
89.2 (86.4 to 91.4)
93.3 (88.3 to 96.3)
89.2 (84.2 to 92.7)
89.9 (87.1 to 92.2)≥2 doses§§
58.0 (54.6 to 61.4)
46.8 (38.2 to 55.5) **
52.5 (44.1 to 60.8)
63.8 (42.9 to 80.6)
51.9 (34.1 to 69.2)
47.5 (36.4 to 58.8)HPV¶¶ vaccine coverage by dosesAll Adolescents≥1 dose
71.1 (69.7 to 72.5)
78.1 (74.7 to 81.2) **
80.0 (77.0 to 82.7) **
85.3 (78.4 to 90.3) **
77.2 (71.4 to 82.0) **
77.9 (73.1 to 82.1) **HPV UTD***
55.4 (53.9 to 56.9)
60.7 (56.9 to 64.4) **
62.7 (59.3 to 66.1) **
66.4 (52.8 to 77.7)
60.9 (54.2 to 67.2)
60.7 (55.7 to 65.5) **FEMALES≥1 dose
72.4 (70.3 to 74.4)
80.0 (75.3 to 84.0) **
84.0 (80.1 to 87.3) **
91.8 (82.5 to 96.4) **
77.0 (68.8 to 83.5)
79.3 (71.2 to 85.6)HPV UTD
57.1 (54.8 to 59.3)
63.9 (58.4 to 69.0) **
67.9 (62.9 to 72.5) **
71.8 (47.0 to 88.0)
62.6 (53.5 to 70.8)
62.8 (55.1 to 69.9)MALES≥1 dose
69.9 (67.9 to 71.8)
76.1 (71.1 to 80.5) **
76.5 (72.1 to 80.4) **
77.1 (66.7 to 85.0)
77.4 (68.8 to 84.1)
76.3 (70.9 to 80.9) **HPV UTD
53.8 (51.7 to 55.9)
57.4 (52.0 to 62.6)
58.3 (53.6 to 63.0)
59.5 (47.2 to 70.7)
59.2 (49.2 to 68.5)
58.2 (51.9 to 64.2)MMR ≥2 doses
93.6 (92.7 to 94.3)
92.7 (90.7 to 94.4)
89.5 (86.9 to 91.7) **
98.3 (95.5 to 99.4) **
91.2 (84.4 to 95.3)
94.3 (92.0 to 96.0)Hepatitis A vaccine ≥2 doses†††
79.9 (78.6 to 81.0)
80.7 (77.7 to 83.4)
85.4 (82.7 to 87.8) **
94.8 (90.5 to 97.2) **
85.6 (79.2 to 90.3) **
85.4 (81.9 to 88.4) **Hepatitis B vaccine ≥3 doses
93.9 (93.1 to 94.6)
92.2 (90.3 to 93.8)
89.6 (87.2 to 91.7) **
94.5 (84.9 to 98.1)
92.1 (85.6 to 95.8)
94.9 (92.8 to 96.5)VaricellaHistory of varicella§§§
8.7 (7.9 to 9.6)
5.3 (3.9 to 7.1) **
9.4 (7.4 to 11.8)
8.2 (5.0 to 13.1)
9.7 (5.8 to 15.9)
6.8 (4.6 to 9.9)Among adolescents with no history of varicella:≥1 dose vaccine
96.3 (95.6 to 96.9)
95.6 (94.1 to 96.7)
93.7 (91.3 to 95.4) **
99.2 (96.6 to 99.8) **
96.2 (93.5 to 97.8)
96.8 (95.1 to 98.0)≥2 doses vaccine
93.0 (92.0 to 93.8)
91.0 (88.8 to 92.8)
89.8 (87.0 to 92.0) **
97.6 (94.6 to 98.9) **
90.2 (82.7 to 94.6)
94.6 (92.4 to 96.1)History of varicella or received ≥2 doses varicella vaccine
93.6 (92.7 to 94.4)
91.5 (89.4 to 93.2)
90.7 (88.2 to 92.8) **
97.8 (95.0 to 99.0) **
91.1 (84.2 to 95.2)
94.9 (92.9 to 96.4)
**Abbreviations:** CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.
* Adolescents (N = 20,163) in the 2020 NIS-Teen were born January 2002 through January 2008.
† Adolescent’s race/ethnicity was reported by their parent or guardian. Adolescents identified in this report as white, black, Asian, American Indian/Alaska Native, or multiracial were reported by the parent or guardian as non-Hispanic. Adolescents identified as multiracial had more than one race category selected. Adolescents identified as Hispanic might be of any race. Native Hawaiian or other Pacific Islanders were not included in the table because of small sample sizes (n= 73).
§ Estimates with 95% confidence interval widths > 20 may not be reliable.
¶Includes percentages receiving Tdap vaccine at age ≥10 years.
** Statistically significant difference (p<0.05) in estimated vaccination coverage by race/ethnicity; referent group was adolescents non-Hispanic whites.
†† Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.
§§ ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.
¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
*** HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior – age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
†††In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. MMWR Recomm Rep 2020;69(No. RR-5):1–38.
§§§ By parent/guardian report or provider records.
Top of PageOnline Supplementary Table 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by Health Insurance Status— National Immunization Survey–Teen, United States, 2020
Online Supplementary Table 2. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by Health Insurance Status— National Immunization Survey–Teen (NIS-Teen), United States, 2020.
Vaccines
Health Insurance Status†, % (95% CI)§Private Insurance Only
(n = 12,004)
Any-Medicaid
(n = 5,937)
Other Insurance
(n = 1,539)
Uninsured
(n = 683)Tdap¶ ≥ 1 dose
91.5 (90.5 to 92.5)
88.4 (86.5 to 90.1) **
89.9 (87.4 to 92.0)
86.3 (80.6 to 90.6) **MenACWY††≥1 dose
90.2 (89.0 to 91.3)
88.6 (86.8 to 90.2)
89.0 (86.2 to 91.2)
85.5 (80.6 to 89.3) **≥2 doses§§
58.1 (54.3 to 61.9)
50.6 (44.1 to 57.1)
54.3 (43.1 to 65.0)
35.5 (22.0 to 51.7) **HPV¶¶ vaccineAll Adolescents≥1 dose
73.3 (71.7 to 74.8)
79.4 (77.3 to 81.3) **
72.1 (68.0 to 75.9)
65.5 (58.4 to 72.0) **HPV UTD***
58.7 (57.0 to 60.3)
61.1 (58.6 to 63.5)
55.1 (50.3 to 59.8)
42.4 (35.3 to 49.9) **FEMALES≥1 dose
75.8 (73.6 to 77.8)
80.0 (77.0 to 82.7) **
75.7 (70.2 to 80.5)
70.9 (61.1 to 79.2)HPV UTD
61.7 (59.3 to 64.0)
62.9 (59.3 to 66.5)
56.0 (49.4 to 62.4)
51.7 (41.3 to 62.1)MALES≥1 dose
70.8 (68.6 to 73.0)
78.8 (76.0 to 81.4) **
68.6 (62.3 to 74.3)
61.2 (51.1 to 70.4)HPV UTD
55.7 (53.4 to 58.0)
59.4 (56.0 to 62.7)
54.1 (47.2 to 61.0)
34.9 (25.9 to 45.2) **MMR ≥2 doses
93.7 (92.9 to 94.4)
90.8 (88.8 to 92.4) **
92.2 ( 89.2 to 94.4)
90.7 (86.6 to 93.6)Hepatitis A vaccine ≥2 doses†††
81.8 (80.5 to 83.0)
83.2 (81.2 to 85.0)
83.4 (79.8 to 86.4)
74.9 (68.5 to 80.3) **Hepatitis B vaccine ≥3 doses
93.6 (92.8 to 94.4)
91.4 (89.6 to 92.8) **
93.9 (91.3 to 95.7)
88.0 (82.7 to 91.8) **VaricellaHistory of varicella§§§
6.6 (5.8 to 7.4)
9.4 (7.9 to 11.0) **
10.8 (7.6 to 14.9) **
18.3 (12.9 to 25.2) **No history of varicella disease≥1 dose vaccine
96.0 (95.3 to 96.6)
95.1 (93.5 to 96.3)
95.2 (92.1 to 97.1)
95.2 (92.6 to 96.9)≥2 doses vaccine
93.0 (92.1 to 93.8)
90.2 (88.1 to 92.0) **
91.6 (88.3 to 94.0)
91.8 (88.8 to 94.1)History of varicella or received ≥2 doses varicella vaccine
93.5 (92.6 to 94.2)
91.1 (89.2 to 92.8) **
92.5 (89.6 to 94.7)
93.3 (90.9 to 95.2)
**Abbreviations:** CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.
* Adolescents (N = 20,163) in the 2020 NIS-Teen were born January 2002 through January 2008.
† Adolescents’ health insurance status was reported by parent or guardian. “Other insurance” includes the Children’s Health Insurance Program (CHIP), military insurance, Indian Health Service, and any other type of health insurance not mentioned elsewhere.
§ Estimates with 95% confidence interval widths > 20 may not be reliable.
¶ Includes percentages receiving Tdap vaccine at age ≥10 years.
** Statistically significant difference (p<0.05) in estimated vaccination coverage by health insurance status; referent group was adolescents with private insurance.
†† Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.
§§ ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.
¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
*** HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior – age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
††† In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. MMWR Recomm Rep 2020;69(No. RR-5):1–38.
§§§ By parent/guardian report or provider records.
Top of PageONLINE SUPPLEMENTARY TABLE 3. Estimated Total Survey Error (TSE) Distribution and Component Error Distributions, National Immunization Survey-Teen, United States, 2020
ONLINE SUPPLEMENTARY TABLE 3. Estimated Total Survey Error (TSE) Distribution and Component Error Distributions, National Immunization Survey-Teen (NIS-Teen), United States, 2020
Vaccine or Series
Component
Mean TSE
(percentage points)
95% Credible Interval
(percentage points)≥1 dose Tdap*
TSE (final weighted)
-6.3
(-7.9, -4.1)TSE (design weighted)
-6.2
(-7.8, -4.0)Noncoverage error
0.1
(-0.1, 1.0)Nonresponse error
-1.3
(-3.3, 1.2)Measurement error
-5.1
(-6.2, -3.7)Sampling error
0.0
(-1.3, 1.6)≥1 dose MenACWY†
TSE (final weighted)
-3.7
(-5.9, -0.9)TSE (design weighted)
-3.9
(-6.0, -1.0)Noncoverage error
0.1
(-0.1, 0.7)Nonresponse error
0.2
(-2.2, 3.2)Measurement error
-4.2
(-5.2, -2.9)Sampling error
0.0
(-1.3, 1.5)UTD for HPV§
TSE (final weighted)
-2.8
(-6.0, 0.5)TSE (design weighted)
-3.9
(-7.1, -0.5)Noncoverage error
0.2
(-0.1, 0.6)Nonresponse error
-1.8
(-5.3, 2.0)Measurement error
-2.3
(-3.9, -0.8)Sampling error
0.0
(-1.5, 1.6)**Abbreviations:** HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.
* Includes percentages receiving Tdap vaccine at age ≥10 years.
† Includes percentages receiving MenACWY or meningococcal-unknown type vaccine.
§ HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.
Top of Page
							
					
						Page last reviewed:  August 12, 2021					Content source: 	National Center for Immunization and Respiratory Diseases homeTeenVaxView Home
TeenVaxView Interactive!
Publications and Resources
Data Sources
Objectives, Targets, and Indicators
For Specific Groupsplus icon
Health Care Professionals
Parents and Preteens/Teens
College and Technical School Students
NIS-Teen Survey Participants
Media ChildVaxView
SchoolVaxView
AdultVaxView
FluVaxView
COVIDVaxView
Association of Immunization Managers (AIM)external icon


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue